SCHEMBL5752341

SCHEMBL5752341

O=C(O)c1ccnc(C2CC2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.47
KDM5A P29375 3/20 0.47
KDM3A Q9Y4C1 2/20 0.47
JMJD1C Q15652 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
GLA P06280 1/20 0.44
HTT P42858 1/20 0.44
HIF1A Q16665 1/20 0.44
LMNA P02545 2/20 0.42
P4HTM Q9NXG6 2/20 0.42
NAPRT Q6XQN6 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
ACMSD Q8TDX5 1/20 0.42
ALDH1A1 P00352 4/20 0.40
KDM5B Q9UGL1 2/20 0.40
KDM6B O15054 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28059189 0.91 KDM4E (0.55) KDM4EKDM5AKDM3AJMJD1CL3MBTL1
SCHEMBL31704503 0.89 KDM4E (0.41) KDM4EKDM5AKDM3AJMJD1CL3MBTL1
SCHEMBL1833909 0.85 GSK3B (0.38) KDM4EKDM5AKDM3AJMJD1CTSHR
SCHEMBL19279418 0.80 CBLB (0.37) KDM4EL3MBTL1TDP1KMT2ASMN1; SMN2
SCHEMBL23166607 0.80 PDE4D (0.43) KDM4EKDM3AL3MBTL1ALDH1A1KDM6B
SCHEMBL31706429 0.79 KDM4E (0.40) KDM4EKDM5AKDM3AJMJD1CL3MBTL1
SCHEMBL1831858 0.79 ALOX5AP (0.43) KDM4EL3MBTL1TDP1KMT2ASMN1; SMN2
SCHEMBL1118328 0.76 CYP1A2 (0.53) KDM4EL3MBTL1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL87765 0.74 KDM4E (0.55) KDM4EKDM5AKDM3AJMJD1CL3MBTL1
SCHEMBL31126262 0.74 KDM4E (0.55) KDM4EKDM5AKDM3AJMJD1CL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4143195-B1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2025-05-21 EP disclosed
US-12024524-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2024-07-02 US disclosed
WO-2024067845-A1 IMIDAZOPYRIDINE COMPOUND AS IRAK4 DEGRADATION AGENT AND USE THEREOF 武汉人福创新药物研发中心有限公司 2024-04-04 WO disclosed
CN-117777126-A Imidazopyridines as IRAK4 degradants and uses thereof 武汉人福创新药物研发中心有限公司 2024-03-29 CN disclosed
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-11-09 US disclosed
US-11702422-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-18 US disclosed
US-11691979-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-04 US disclosed
CN-115884810-A Imidazopyridazines as IL-17 modulators 詹森药业有限公司 2023-03-31 CN disclosed
US-20230081548-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-03-16 US disclosed
EP-4143195-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 Janssen Pharmaceutica NV (BE) 2023-03-08 EP disclosed
US-20220402922-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN RESEARCH & DEVELOPMENT, LLC 2022-12-22 US disclosed
WO-2021222404-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN BIOTECH, INC. (US) 2021-11-04 WO disclosed
CN-103249721-A Arylamine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC 2013-08-14 CN disclosed
WO-2009131815-A1 1,5-DIPHENYL-PYRROLIDIN-2-ONE COMPOUNDS AS CB-1 LIGANDS ELI LILLY AND COMPANY (US) 2009-10-29 WO disclosed
EP-1694651-A1 HERBICIDAL PYRIMIDINES E.I.Du pont de nemours and company (US) 2006-08-30 EP disclosed
WO-2005063721-A1 HERBICIDAL PYRIMIDINES E.I. DUPONT DE NEMOURS AND COMPANY (US) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691979-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 KDM4E 2583/4885KDM5A 1220/4885KDM3A 1535/4885
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 KDM4E 2583/4885KDM5A 1220/4885KDM3A 1535/4885
US-12024524-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 KDM4E 2583/4885KDM5A 1220/4885KDM3A 1535/4885
US-20230081548-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 KDM4E 2583/4885KDM5A 1220/4885KDM3A 1535/4885
US-20220402922-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 KDM4E 2583/4885KDM5A 1220/4885KDM3A 1535/4885
US-11702422-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 KDM4E 2583/4885KDM5A 1220/4885KDM3A 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.